Clinical Trials Logo

Clinical Trial Summary

To quantify the role of drugs and other factors in the etiology of agranulocytosis and aplastic anemia.


Clinical Trial Description

BACKGROUND:

Agranulocytosis and aplastic anemia are rare but serious blood diseases that can be caused by drugs and other environmental factors. In 1980, there were only limited quantitative estimates of the risk between various exposures, particularly drugs, and the two dyscrasias. The data were collected in the IAAAS, a multicenter population-based case-control study conducted from 1980 to 1986 in eight regions. The study was funded by a pharmaceutical company to investigate a single hypothesis, but information was obtained on all drugs and on other factors, enabling a general investigation of the dyscrasias.

DESIGN NARRATIVE:

The study was for retrospective data analysis only. Standard case-control methods were used. In most instances, multivariate analysis was used to control confounding, especially by simultaneous use of other causal drugs. Adverse effects and the relative safety of drugs in relation to the two dyscrasias were documented. Because the IAAAS was population-based, incidence rates were provided directly, and excess risks were estimated for associated drugs. Such quantitative measures of association were generally unavailable. Among the drugs that were analyzed were various categories such as psychotropics, antihistamines, and cardiovascular drugs, and individual drugs such as allopurinol. Factors other than drugs were also evaluated, including exposure to radiation and chemicals such as benzene and insecticides, history of viral infection, and history of allergy and other conditions.

The study completion date listed in this record was obtained from the "End Date" entered in the Protocol Registration and Results System (PRS) record. ;


Study Design

N/A


Related Conditions & MeSH terms


NCT number NCT00005307
Study type Observational
Source National Heart, Lung, and Blood Institute (NHLBI)
Contact
Status Completed
Phase N/A
Start date April 1989
Completion date March 1991

See also
  Status Clinical Trial Phase
Recruiting NCT00106015 - Diamond Blackfan Anemia Registry (DBAR)
Completed NCT00059293 - Transcranial Doppler (TCD) Ultrasound of Subjects Enrolled in BABY HUG - Ancillary to BABY HUG
Completed NCT00023530 - Blood and Marrow Transplant Clinical Research Network N/A
Not yet recruiting NCT05983536 - The Evaluation of Anti-interference Ability and Clinical Specificity of HIV Ag +Ab Assay Kit (Sysmex)
Recruiting NCT03548766 - Using DNA-Typing and Erythrocyte Microparticle Analysis to Detect Blood Doping Phase 3
Completed NCT00007371 - Hepatitis C in Clinically Discordant Hemophilic Siblings N/A
Completed NCT00005682 - Aplastic Anemia Epidemiology: Incidence and Case-control N/A
Completed NCT00000587 - Erythropoietin for Anemia Due to Zidovudine in Human Immunodeficiency Virus Infection Phase 2
Completed NCT00005305 - Hepatitis Delta Infections in Hemophiliacs N/A
Completed NCT00005304 - Delta Hepatitis and Liver Disease in Hemophiliacs
Completed NCT00005277 - Cooperative Study of The Clinical Course of Sickle Cell Disease N/A
Completed NCT00035763 - Pain in Sickle Cell Epidemiologic Study N/A
Completed NCT00005300 - Investigation of Selected Patient Groups From The Cooperative Study of Sickle Cell Disease N/A
Recruiting NCT04600609 - Examining the Experiences of Children With Blood Disorders
Not yet recruiting NCT03881917 - Cystatin c and Beta 2 Microglobulin in Thalassemic Children.
Completed NCT00005556 - Retention of Bone Marrow Donors in a National Registry N/A
Completed NCT00000597 - Multi-Center Trial of Anti-Thymocyte Globulin in Treatment of Aplastic Anemia and Other Hematologic Disorders Phase 3
Completed NCT03586180 - Medical Clowning: Needs Assessment and Implication for Hospitalized Children With Cancer/Blood Disease
Recruiting NCT03848962 - Collection and Distribution of Biospecimens for Novel Research Uses
Terminated NCT00486720 - Phase IIa Vorinostat (MK0683, Suberoylanilide Hydroxamic Acid (SAHA)) Study in Lower Risk Myelodysplastic Syndromes (0683-064) Phase 2